Press releases

17 Nov 2020

UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

12 Nov 2020

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

10 Nov 2020

Disposals of own shares

6 Nov 2020

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

31 Oct 2020

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients

30 Oct 2020

Disposals of own shares

Press releases

Press releases

Search Press releases

UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Disposals of own shares

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients

Disposals of own shares

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Disposals of own shares

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients

Disposals of own shares

Choose a Country